The dipeptidyl peptidase (DPP)‐4 inhibitors are a new class of antihyperglycaemic agents
which were developed for the treatment of type 2 diabetes by rational drug design, based on …

Objective To assess the efficacy and safety of dipeptidyl peptidase-4 (DPP-4) inhibitors
compared with metformin as monotherapy, or with other commonly used hypoglycaemic …

Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a
sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We …

Background Metformin is an oral anti‐hyperglycemic agent that has been shown to reduce
total mortality compared to other anti‐hyperglycemic agents, in the treatment of type 2 …

ContextPharmacotherapies that augment the incretin pathway have recently become
available, but their role in the management of type 2 diabetes is not well defined …

Context Metformin is the recommended initial drug therapy for patients with type 2 diabetes
mellitus (DM). However, the optimal second-line drug when metformin monotherapy fails is …

Introduction: Additional oral antidiabetic agents to metformin, sulfonylureas (SU) and
thiazolidinediones (TZD) are approved for the treatment of type 2 diabetes. Areas covered …

Objectives To examine the association between dipeptidyl peptidase-4 (DPP-4) inhibitors
and the risk of heart failure or hospital admission for heart failure in patients with type 2 …

Type 2 diabetes (T2DM) is a progressive disease, and pharmacotherapy with a single agent
does not generally provide durable glycaemic control over the long term. Sulphonylurea …

The primary cause of hypoglycaemia in Type 2 diabetes is diabetes medication—in
particular, those which raise insulin levels independently of blood glucose, such as …